Sign in Sign up for free

Last updated: 17 June 2024 at 4:41pm EST

Keith Brownlie Net Worth




The estimated Net Worth of Keith L Brownlie is at least $2.15 Million dollars as of 9 April 2015. Mr. Brownlie owns over 14,286 units of Celldex Therapeutics stock worth over $2,082,000 and over the last 13 years he sold CLDX stock worth over $0. In addition, he makes $67,190 as Independent Director at Celldex Therapeutics.

Mr. Brownlie CLDX stock SEC Form 4 insiders trading

Keith has made over 3 trades of the Celldex Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 14,286 units of CLDX stock worth $8,714 on 9 April 2015.

The largest trade he's ever made was buying 19,047 units of Celldex Therapeutics stock on 25 June 2013 worth over $19,999. On average, Keith trades about 2,000 units every 26 days since 2011. As of 9 April 2015 he still owns at least 50,000 units of Celldex Therapeutics stock.

You can see the complete history of Mr. Brownlie stock trades at the bottom of the page.





Keith Brownlie biography

Keith L. Brownlie CPA serves as Independent Director of the Company. Mr. Brownlie was employed by the accounting firm Ernst & Young LLP from 1974 to 2010. At Ernst & Young, he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York Metro Area. From 2010 until 2019, Mr. Brownlie served as a member of the board of directors and chairman of the audit committee of Soligenix, Inc., a publicly held biopharmaceutical company. From 2012 until 2019, Mr. Brownlie served as a member of the board of directors and served as the chairman of the audit committee of Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation), a publicly held biopharmaceutical company. From 2011 to 2013, Mr. Brownlie also served as a member of the board of directors and served as the chairman of the audit committee of EpiCept Corporation, a publicly held biopharmaceutical company. From 2013 to 2014, Mr. Brownlie was a member of the board of directors and served as the chairman of the audit committee of Cancer Genetics, Inc., a publicly held biopharmaceutical company. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.

What is the salary of Keith Brownlie?

As the Independent Director of Celldex Therapeutics, the total compensation of Keith Brownlie at Celldex Therapeutics is $67,190. There are 14 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.



How old is Keith Brownlie?

Keith Brownlie is 67, he's been the Independent Director of Celldex Therapeutics since 2017. There are 4 older and 20 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.

What's Keith Brownlie's mailing address?

Keith's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.



What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im



What does Celldex Therapeutics's logo look like?

Celldex Therapeutics Inc. logo

Complete history of Mr. Brownlie stock trades at Cancer Genetics, Celldex Therapeutics, Soligenix Inc, and Phio Pharmaceuticals

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
9 Apr 2015 SNGX Soligenix Inc Keith L Brownlie
Director
 Option 14,286 $0.61 $8,714
9 Apr 2015
50,000 ↗
14 May 2014 SNGX Soligenix Inc Keith L Brownlie
Director
 Option 16,667 $0.30 $5,000
14 May 2014
35,714 ↗
25 Jun 2013 SNGX Soligenix Inc Keith L Brownlie
Director
 Buy 19,047 $1.05 $19,999
25 Jun 2013
19,047 ↗


Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include: